A serum exosomal microRNA-based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma

Jin-Seong Hwang , Sugi Lee , Gyeonghwa Kim , Hoibin Jeong , Kiyoon Kwon , Eunsun Jung , Yuna Roh , Taesang Son , Hana Lee , Moo-Seung Lee , Kyoung-Jin Oh , Hye Won Lee , Yu Rim Lee , Soo Young Park , Won Young Tak , Hyun Seung Ban , Hyun-Soo Cho , Mi-Young Son , Jang-Seong Kim , Keun Hur , Dae-Soo Kim , Tae-Su Han

Cancer Communications ›› 2025, Vol. 45 ›› Issue (9) : 1188 -1193.

PDF
Cancer Communications ›› 2025, Vol. 45 ›› Issue (9) : 1188 -1193. DOI: 10.1002/cac2.70043
LETTER TO THE JOURNAL

A serum exosomal microRNA-based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma

Author information +
History +
PDF

Cite this article

Download citation ▾
Jin-Seong Hwang, Sugi Lee, Gyeonghwa Kim, Hoibin Jeong, Kiyoon Kwon, Eunsun Jung, Yuna Roh, Taesang Son, Hana Lee, Moo-Seung Lee, Kyoung-Jin Oh, Hye Won Lee, Yu Rim Lee, Soo Young Park, Won Young Tak, Hyun Seung Ban, Hyun-Soo Cho, Mi-Young Son, Jang-Seong Kim, Keun Hur, Dae-Soo Kim, Tae-Su Han. A serum exosomal microRNA-based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma. Cancer Communications, 2025, 45(9): 1188-1193 DOI:10.1002/cac2.70043

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-49.

[2]

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12-49.

[3]

Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022; 28(2): 216-29.

[4]

Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan H, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024; 23(1): 189.

[5]

Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013; 13(2): 123-35.

[6]

Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: Current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019; 16(7): 411-28.

[7]

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015; 13(4): 643-e40.

[8]

Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis, and liver cancer. J Hepatol. 2018; 69(2): 385-95.

[9]

Wang Y, Zhang C, Zhang P, Guo G, Jiang T, Zhao X, et al. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med. 2018; 7(5): 1670-9.

[10]

Sohn W, Kim J, Kang SH, Yang SR, Cho JY, Cho HC, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 2015; 47(9): e184.

[11]

Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011; 29(36): 4781-8.

[12]

Xue X, Zhao Y, Wang X, Qin L, Hu R. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. J Cell Biochem. 2019; 120(1): 135-42.

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.

AI Summary AI Mindmap
PDF

25

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/